Role of miR-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines
Tania Diaz PhD
Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain
Search for more papers by this authorRut Tejero MSc
Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain
Search for more papers by this authorIsabel Moreno MD
Department of Medical Oncology and Surgery, Hospital Municipal de Badalona, Badalona, Spain
Search for more papers by this authorGerardo Ferrer PhD
Laboratory of Translational Hematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
Search for more papers by this authorAnna Cordeiro MSc
Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain
Search for more papers by this authorRosa Artells PhD
Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain
Search for more papers by this authorAlfons Navarro PhD
Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain
Search for more papers by this authorRaquel Hernandez MD
Department of Medical Oncology and Surgery, Hospital Municipal de Badalona, Badalona, Spain
Search for more papers by this authorGustavo Tapia MD
Department of Pathology, Hospital Germans Trias i Pujol, Badalona, Spain
Search for more papers by this authorCorresponding Author
Mariano Monzo MD, PhD
Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain
Correspondence to: Mariano Monzo, MD, PhD, Department of Human Anatomy, Embryology School of Medicine, University of Barcelona, Casanovas 143 08036, Barcelona, Spain.
Fax: +34-934035263. E-mail: [email protected]
Search for more papers by this authorTania Diaz PhD
Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain
Search for more papers by this authorRut Tejero MSc
Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain
Search for more papers by this authorIsabel Moreno MD
Department of Medical Oncology and Surgery, Hospital Municipal de Badalona, Badalona, Spain
Search for more papers by this authorGerardo Ferrer PhD
Laboratory of Translational Hematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
Search for more papers by this authorAnna Cordeiro MSc
Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain
Search for more papers by this authorRosa Artells PhD
Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain
Search for more papers by this authorAlfons Navarro PhD
Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain
Search for more papers by this authorRaquel Hernandez MD
Department of Medical Oncology and Surgery, Hospital Municipal de Badalona, Badalona, Spain
Search for more papers by this authorGustavo Tapia MD
Department of Pathology, Hospital Germans Trias i Pujol, Badalona, Spain
Search for more papers by this authorCorresponding Author
Mariano Monzo MD, PhD
Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain
Correspondence to: Mariano Monzo, MD, PhD, Department of Human Anatomy, Embryology School of Medicine, University of Barcelona, Casanovas 143 08036, Barcelona, Spain.
Fax: +34-934035263. E-mail: [email protected]
Search for more papers by this authorAbstract
Background and Objectives
Surgery is the standard treatment for colorectal cancer (CRC), and adjuvant chemotherapy has been shown to be effective in stage III but less so in stage II. We have analyzed the expression of the miR-200 family in tissue samples from resected CRC patients and correlated our findings with survival to adjuvant treatment with fluoropyrimidines.
Methods
Tumor tissue samples were obtained from 127 surgically resected patients with stage I–III CRC. miRNA detection was performed using TaqMan MicroRNA assays.
Results
High levels of miR-200a and miR-200c were associated with longer overall survival, while high levels of miR-429 correlated with longer overall and disease-free survival (DFS). In the subgroup of 56 patients treated with fluoropyrimidines and in the smaller subgroup of 32 stage II patients treated with fluoropyrimidines, those with high levels of miR-200a, miR-200c, miR-141, or miR-429 had significantly longer overall and DFS. Low miR-429 levels were identified as an independent prognostic marker. High levels of miR-429 combined with 5-fluorouracil inhibited cell invasion in LOVO cells.
Conclusions
miR-200a, miR-200c, miR-141, and miR-429 expression levels may identify CRC patients, including those with stage II disease, who are most likely to benefit from adjuvant chemotherapy. J. Surg. Oncol 2014; 109:676–683. © 2014 Wiley Periodicals, Inc.
Supporting Information
Additional supporting information may be found in the online version of this article at the publisher's web-site.
| Filename | Description |
|---|---|
| jso23572-sm-0001-SupFig-S1.tif766.8 KB | Supplementary Figure S1. |
| jso23572-sm-0002-SupFig-S2.tif708.4 KB | Supplementary Figure S2. |
| jso23572-sm-0003-SupFig-S3.tif2.3 MB | Supplementary Figure S3. |
| jso23572-sm-0004-SupFig-S4.tif321.8 KB | Supplementary Figure S4. |
| jso23572-sm-0005-SupFig-S5.tif3.5 MB | Supplementary Figure S5. |
| jso23572-sm-0006-SupTab-S1.doc48 KB | Supplementary Table S1. |
| jso23572-sm-0007-SupFigsLegend-S1.doc22.5 KB | Supplementary Figures Legend. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1 Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11–30.
- 2 Gray R, Barnwell J, McConkey C, et al.: Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 2007; 370: 2020–2029.
- 3 Twelves C, Wong A, Nowacki MP, et al.: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696–2704.
- 4 Chibaudel B, Tournigand C, Andre T, et al.: Targeted therapies as adjuvant treatment for early-stage colorectal cancer: First impressions and clinical questions. Clin Colorectal Cancer 2010; 9: 269–273.
- 5 Tellez CS, Juri DE, Do K, et al.: EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res 2011; 71: 3087–3097.
- 6 Schliekelman MJ, Gibbons DL, Faca VM, et al.: Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer. Cancer Res 2011; 71: 7670–7682.
- 7 Korpal M, Ell BJ, Buffa FM, et al.: Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 2011; 17: 1101–1108.
- 8 Mongroo PS, Rustgi AK: The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol Ther 2010; 10: 219–222.
- 9 Gregory PA, Bert AG, Paterson EL, et al.: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593–601.
- 10 Park SM, Gaur AB, Lengyel E, et al.: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894–907.
- 11 Hurteau GJ, Carlson JA, Roos E, et al.: Stable expression of miR-200c alone is sufficient to regulate TCF8 (ZEB1) and restore E-cadherin expression. Cell Cycle 2009; 8: 2064–2069.
- 12 Chang KH, Miller N, Kheirelseid EA, et al.: MicroRNA signature analysis in colorectal cancer: Identification of expression profiles in stage II tumors associated with aggressive disease. Int J Colorectal Dis 2011; 26: 1415–1422.
- 13 Zhu W, Xu H, Zhu D, et al.: miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012; 69: 723–731.
- 14 Kahlert C, Lahes S, Radhakrishnan P, et al.: Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin Cancer Res 2011; 17: 7654–7663.
- 15 Monzo M, Navarro A, Bandres E, et al.: Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell Res 2008; 18: 823–833.
- 16 Gravgaard KH, Lyng MB, Laenkholm AV, et al.: The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. Breast Cancer Res Treat 2012; 134: 207–217.
- 17 Barron N, Keenan J, Gammell P, et al.: Biochemical relapse following radical prostatectomy and miR-200a levels in prostate cancer. Prostate 2012; 72: 1193–1199.
- 18 Lee JW, Park YA, Choi JJ, et al.: The expression of the miRNA-200 family in endometrial endometrioid carcinoma. Gynecol Oncol 2011; 120: 56–62.
- 19 Mateescu B, Batista L, Cardon M, et al.: miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med 2011; 17: 1627–1635.
- 20 Hur K, Toiyama Y, Takahashi M, et al.: MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 2013; 62: 1315–1326.
- 21 Hothorn TLB: On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal 2003; 43: 121–137.
- 22 Brabletz T, Jung A, Reu S, et al.: Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA 2001; 98: 10356–10361.
- 23 Chaffer CL, Brennan JP, Slavin JL, et al.: Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: Role of fibroblast growth factor receptor-2. Cancer Res 2006; 66: 11271–11278.
- 24 Saydam O, Shen Y, Wurdinger T, et al.: Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol 2009; 29: 5923–5940.
- 25 Sun T, Wang C, Xing J: et al.: miR-429 modulates the expression of c-myc in human gastric carcinoma cells. Eur J Cancer 2011; 47: 2552–2559.
- 26 Toiyama Y, Hur K, Tanaka K, et al.: Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg. 2013 Aug 26. [Epub ahead of print]
- 27 Li Y, Li W, Yang Y, et al.: MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res 2009; 1286: 13–18.
- 28 Zhu W, Shan X, Wang T, et al.: miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010; 127: 2520–2529.
- 29 Hummel R, Hussey DJ, Haier J: MicroRNAs: Predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 2010; 46: 298–311.
- 30 Pogribny IP, Filkowski JN, Tryndyak VP, et al.: Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 2010; 127: 1785–1794.
- 31 Meng F, Henson R, Lang M, et al.: Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006; 130: 2113–2129.
- 32 Longley DB, Harkin DP, Johnston PG: 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330–338.
